Mannitol Injection, Solution
NDC Package 63323-024-25
Package Information
Mannitol injection is • Well established anuria due to severe renal disease. • Severe pulmonary congestion or frank pulmonary edema. • Active intracranial bleeding except during craniotomy. • Severe dehydration. • Progressive renal damage or dysfunction after institution of mannitol therapy, including increasing oliguria and azotemia. • Progressive heart failure or pulmonary congestion after mannitol therapy is started. This formulation utilizes a injection, solution delivery system. Marketed by Fresenius Kabi Usa, Llc, this product is identified by NDC 63323-024 and is authorized under FDA application ANDA080677.
Identification & Billing
- RxCUI: 311450 - mannitol 25 % in 50 ML Injection
- RxCUI: 311450 - 50 ML mannitol 250 MG/ML Injection
- RxCUI: 311450 - mannitol 12.5 GM per 50 ML Injection
- RxCUI: 311450 - mannitol 25 % per 50 ML Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 63323 - Fresenius Kabi Usa, Llc
- 63323-024 - Mannitol
- 63323-024-25 - 25 VIAL, SINGLE-DOSE in 1 TRAY / 50 mL in 1 VIAL, SINGLE-DOSE (63323-024-01)
- 63323-024 - Mannitol
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (63323-024). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 63323-024-25 identifies a specific commercial package of 25 vial, single-dose in 1 tray / 50 ml in 1 vial, single-dose (63323-024-01) of Mannitol, a human prescription drug labeled by Fresenius Kabi Usa, Llc. This injection, solution is formulated for intravenous use and contains mannitol as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Fresenius Kabi Usa, Llc on March 19, 2000. The current certification is valid through December 31, 2026.
How is this Fresenius Kabi Usa, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 63323002425. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
